Strontium compound for treatment of sub-dermal soft tissue pain

Abstract

The invention provides a method of treatment of a human or non-human subject to combat sub-dermal soft tissue pain therein, said method comprising administering to a subject in need thereof an effective amount of a physiologically tolerable strontium compound.

1 - 8 . (canceled) 
     
     
         9 . A method of treatment of a human or non-human subject to combat sub-dermal soft tissue pain therein, said method comprising administering to a said subject in need thereof an effective amount of a physiologically tolerable strontium compound. 
     
     
         10 . A method as claimed in  claim 9 , wherein said strontium compound is administered to the surface of the skin. 
     
     
         11 . A method as claimed in either of  claims 9  and  10 , wherein said soft tissue is muscle. 
     
     
         12 . The use of a physiologically tolerable strontium compound for the manufacture of a medicament for use in the treatment of sub-dermal soft tissue pain. 
     
     
         13 . A pain relieving topical pharmaceutical composition comprising a physiologically tolerable strontium compound, a physiologically tolerable carrier and a physiologically tolerable skin penetration enhancing agent. 
     
     
         14 . A composition as claimed in  claim 13 , wherein said skin penetration enhancing agent is dimethylsulphoxide. 
     
     
         15 . A pain relieving pharmaceutical composition comprising a physiologically tolerable strontium compound and a physiologically tolerable bioadhesive, optionally together with a physiologically tolerable carrier or excipient. 
     
     
         16 . A composition as claimed in any one of  claims 13  to  15 , wherein said strontium compound is strontium chloride or strontium nitrate. 
     
     
         17 . An iontophoretic assembly comprising a cathode in electrical contact with a drug reservoir, characterized in that said drug reservoir contains a physiologically tolerable strontium compound. 
     
     
         18 . A salt or complex of strontium and a physiologically tolerable non-salicylate, non-oxicam cyclooxygenase inhibitor. 
     
     
         19 . A pharmaceutical composition comprising a salt or complex of strontium and a physiologically tolerable non-salicylate, non-oxicam cyclooxygenase inhibitor together with a pharmaceutical carrier or excipient. 
     
     
         20 . A salt or complex of strontium and an alpha amino acid. 
     
     
         21 . A pharmaceutical composition comprising a salt or complex of strontium and an alpha amino acid together with a pharmaceutical carrier or excipient. 
     
     
         22 . A salt or complex of strontium and a physiologically tolerable diethylenetriamine- or tetraazacyclododecane-backboned chelating agent. 
     
     
         23 . A pharmaceutical composition comprising a salt or complex of strontium and a physiologically tolerable diethylenetriamine- or tetraazacyclododecane-backboned chelating agent together with a pharmaceutical carrier or excipient. 
     
     
         24 . The use of a physiologically tolerable strontium compound for the manufacture of a medicament for use in the treatment of herpetic infection. 
     
     
         25 . A method of treatment of a human or other mammalian subject experiencing symptoms of herpetic infection, said method comprising administering to said subject an effective amount of a physiologically tolerable strontium compound.